Literature DB >> 16397505

Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors.

T McKay1, M Patel, R J Pickles, L G Johnson, J C Olsen.   

Abstract

Lentivirus-based gene transfer has the potential to efficiently deliver DNA-based therapies into non-dividing epithelial cells of the airway for the treatment of lung diseases such as cystic fibrosis. However, significant barriers both to lung-specific gene transfer and to production of lentivirus vectors must be overcome before these vectors can be routinely used for applications to the lung. In this study, we investigated whether the ability to produce lentiviral vectors pseudotyped with fowl plague virus hemagglutinin (HA) could be improved by co-expression of influenza virus M2 in vector-producing cells. We found that M2 expression led to a 10-30-fold increase in production of HA-pseudotyped lentivirus vectors based upon equine infectious anemia virus (EIAV) or human immunodeficiency virus type 1 (HIV-1). Experiments using the M2 inhibitor amantadine and a drug-resistant mutant of M2 established that the ion channel activity of M2 was important for M2-dependent augmentation of vector production. Furthermore, the neuraminidase activity necessary for particle release from producer cells could also be incorporated into producer cells by co-expression of influenza NA cDNA. Lentiviral vectors pseudotyped with influenza envelope proteins were able to efficiently transduce via the apical membrane of polarized mouse tracheal cultures in vitro as well as mouse tracheal epithelia in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16397505     DOI: 10.1038/sj.gt.3302715

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  41 in total

1.  Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes.

Authors:  Katsuyuki Mitomo; Uta Griesenbach; Makoto Inoue; Lucinda Somerton; Cuixiang Meng; Eiji Akiba; Toshiaki Tabata; Yasuji Ueda; Gad M Frankel; Raymond Farley; Charanjit Singh; Mario Chan; Felix Munkonge; Andrea Brum; Stefania Xenariou; Sara Escudero-Garcia; Mamoru Hasegawa; Eric W F W Alton
Journal:  Mol Ther       Date:  2010-03-23       Impact factor: 11.454

2.  Proteolytic activation of the 1918 influenza virus hemagglutinin.

Authors:  Chawaree Chaipan; Darwyn Kobasa; Stephanie Bertram; Ilona Glowacka; Imke Steffen; Theodros Solomon Tsegaye; Makoto Takeda; Thomas H Bugge; Semi Kim; Youngwoo Park; Andrea Marzi; Stefan Pöhlmann
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

3.  Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.

Authors:  Yinghua Tang; Ziying Yan; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2020-04-15       Impact factor: 5.695

Review 4.  Advances in cell and gene-based therapies for cystic fibrosis lung disease.

Authors:  Mayumi Oakland; Patrick L Sinn; Paul B McCray
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

5.  Human CRM1 augments production of infectious human and feline immunodeficiency viruses from murine cells.

Authors:  Hila Elinav; Yuanfei Wu; Ayse Coskun; Katarzyna Hryckiewicz; Iris Kemler; Yani Hu; Hilary Rogers; Bing Hao; Choukri Ben Mamoun; Eric Poeschla; Richard Sutton
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

6.  Influenza Hemifusion Phenotype Depends on Membrane Context: Differences in Cell-Cell and Virus-Cell Fusion.

Authors:  Katarzyna E Zawada; Kenta Okamoto; Peter M Kasson
Journal:  J Mol Biol       Date:  2018-02-02       Impact factor: 5.469

7.  Characterization of a trypsin-dependent avian influenza H5N1-pseudotyped HIV vector system for high throughput screening of inhibitory molecules.

Authors:  Zhujun Ao; Ami Patel; Kaylie Tran; Xinying He; Keith Fowke; Kevin Coombs; Darwyn Kobasa; Gary Kobinger; Xiaojian Yao
Journal:  Antiviral Res       Date:  2008-03-06       Impact factor: 5.970

8.  High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors.

Authors:  Manij Patel; Angela M Giddings; John Sechelski; John C Olsen
Journal:  J Gene Med       Date:  2013-01       Impact factor: 4.565

9.  Lentivirus vector can be readministered to nasal epithelia without blocking immune responses.

Authors:  Patrick L Sinn; Ariadna C Arias; Kim A Brogden; Paul B McCray
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

10.  CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.

Authors:  Liqun Zhang; Brian Button; Sherif E Gabriel; Susan Burkett; Yu Yan; Mario H Skiadopoulos; Yan Li Dang; Leatrice N Vogel; Tristan McKay; April Mengos; Richard C Boucher; Peter L Collins; Raymond J Pickles
Journal:  PLoS Biol       Date:  2009-07-21       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.